Document is current

Any future updates will be listed below

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Crossref DOI link: https://doi.org/10.1007/s00262-024-03750-1

Published Online: 2024-07-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark